Inimmune Advances Phase 2 Trial of INI-2004, Aiming to Transform Allergic Rhinitis Treatment Inimmune has completed enrollment in its Phase 2 trial for INI-2004, an innovative treatment for allergic rhinitis, expected to yield crucial data soon.

Inimmune Advances Phase 2 Trial of INI-2004, Aiming to Transform Allergic Rhinitis Treatment #United_States #Missoula #Allergic_Rhinitis #INI-2004 #Inimmune_Corporation

A Survey Reveals Half of Allergic Rhinitis Sufferers Hesitate to Seek Treatment This article explores a survey revealing that over half of those suffering from allergic rhinitis hesitate to seek treatment due to long wait times in hospitals, highlighting a need for improved access to care.

A Survey Reveals Half of Allergic Rhinitis Sufferers Hesitate to Seek Treatment #Japan #Tokyo #online_consultation #Allergic_Rhinitis #Fit_Clinic

Inimmune Launches Critical Phase 2 Trial for Allergy Treatment INI-2004 Inimmune Corporation has initiated its Phase 2 clinical trial to evaluate INI-2004 for allergic rhinitis, aiming to provide new lasting relief for patients.

Inimmune Launches Critical Phase 2 Trial for Allergy Treatment INI-2004 #Canada #Kingston #Allergic_Rhinitis #INI-2004 #Inimmune

Groundbreaking Phase III Results of Stapokibart for Treating Seasonal Allergic Rhinitis Published in Nature Medicine Keymed's Stapokibart, an IL-4Rα monoclonal antibody, shows promising results in treating moderate-to-severe seasonal allergic rhinitis, as published in Nature Medicine.

Groundbreaking Phase III Results of Stapokibart for Treating Seasonal Allergic Rhinitis Published in Nature Medicine #China #Chengdu #Stapokibart #Allergic_Rhinitis #Keymed

New Clinical Study Validates the Benefits of SEBclausii™ in Allergic Rhinitis Treatment A recent clinical trial demonstrates that SEBclausii™ effectively alleviates symptoms of acute allergic rhinitis, showcasing its safety and efficacy, and enhancing immune function.

New Clinical Study Validates the Benefits of SEBclausii™ in Allergic Rhinitis Treatment #USA #Chino #Allergic_Rhinitis #Specialty_Enzymes #SEBclausii™

Keymed Biosciences Receives Regulatory Approval for Stapokibart, a New Treatment for Allergic Rhinitis Keymed Biosciences has announced the approval of its new drug Stapokibart, which targets seasonal allergic rhinitis, enhancing patient care in China.

Keymed Biosciences Receives Regulatory Approval for Stapokibart, a New Treatment for Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Allergic_Rhinitis